Renal failure therapy machines and methods including conductive and convective clearance
US-9216246-B2 · Dec 22, 2015 · US
US9440019B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9440019-B2 |
| Application number | US-201113806184-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 22, 2011 |
| Priority date | Jun 24, 2010 |
| Publication date | Sep 13, 2016 |
| Grant date | Sep 13, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a sorption agent for removing endotoxins from a biological fluid, comprising a water-insoluble, porous carrier having a neutral hydrophobic surface wherein the surface of the carrier has an adsorptive coating made of polymyxin and albumin, wherein polymyxin and albumin are bonded to the surface of the carrier in a noncovalent manner. The invention further relates to a method for producing such a sorption agent. The sorption agent is used in extracorporeal blood purification, in particular in order to treat individuals, who have sepsis.
Opening claim text (preview).
The invention claimed is: 1. A sorption agent for removing endotoxins from blood or blood plasma, comprising: a water-insoluble, porous carrier having a neutral hydrophobic surface wherein the surface of the carrier has an adsorptive coating made of polymyxin B and human serum albumin, wherein the polymyxin B and human serum albumin are noncovalently attached to the surface of the carrier by a hydrophobic interaction. 2. The sorption agent according to claim 1 , wherein the carrier is a hydrophobic polymer. 3. The sorption agent according to claim 2 , wherein the hydrophobic polymer is a cross-linked polystyrene polymer. 4. The sorption agent according to claim 1 , wherein the carrier has a mean pore size of at least 15 nm. 5. The sorption agent according to claim 1 , wherein the carrier has a mean pore size of not greater than 120 nm. 6. The sorption agent according to claim 1 , wherein the sorption agent has the form of microparticles. 7. The sorption agent according to claim 6 , wherein the microparticles have a particle size of 20 μm or less. 8. A sorption apparatus, containing the sorption agent according to claim 1 . 9. A plasma circuit, containing a suspension of the sorption agent according to claim 1 . 10. A method of producing a sorption agent according to claim 1 , comprising the steps of: a) providing a water-insoluble, porous carrier which has a neutral, hydrophobic surface, b) adsorptively coating the surface of the carrier with polymyxin B by contacting and incubating the carrier with an aqueous, polymyxin B-containing solution, c) washing the carrier to remove any unbound polymyxin B, d) adsorptively coating the polymyxin B-coated surface of the carrier with human serum albumin by contacting and incubating the carrier with an aqueous, human serum albumin-containing solution, and e) as appropriate, washing the carrier to remove any unbound human serum albumin. 11. The method according to claim 10 , wherein the carrier is autoclaved between the steps b) and c) or between the steps c) and d). 12. A method for removing endotoxins from blood or blood plasma, comprising: bringing blood or blood plasma contaminated with endotoxins into contact with the sorption agent according to claim 1 . 13. The method according to claim 12 , carried out for the treatment of a sepsis. 14. The method according to claim 12 , wherein the sorption agent is included in a Microspheres-based Detoxification System (MDS). 15. The sorption agent according to claim 3 , wherein the hydrophobic polymer is a polystyrene-divinyl benzene copolymer. 16. The sorption agent according to claim 4 , wherein the carrier has a mean pore size of at least 30 nm. 17. The sorption agent according to claim 7 , wherein the microparticles have a particle size of 8 μm or less. 18. The sorption agent according to claim 7 , wherein the microparticles have a particle size of 5 μm or less.
Proteins, nucleic acids, polysaccharides, antibodies or antigens · CPC title
consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds · CPC title
Cross-linked polymers · CPC title
comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures · CPC title
the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.